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Cocoa supplementation has been associated with beneﬁts to cardiovascular health.
However, cocoa’s effects on cognition are less clear. A randomized, placebo-controlled,
double-blind clinical trial (n = 40, age M = 24.13 years, SD = 4.47 years) was
conducted to investigate the effects of both acute (same-day) and sub-chronic (daily
for four-weeks) 250mg cocoa supplementation on mood and mental fatigue, cognitive
performance and cardiovascular functioning in young, healthy adults. Assessment
involved repeated 10-min cycles of the Cognitive Demand Battery (CDB) encompassing
two serial subtraction tasks (Serial Threes and Sevens), a Rapid Visual Information
Processing task, and a mental fatigue scale over the course of half an hour. The
Swinburne University Computerized Cognitive Assessment Battery (SUCCAB) was
also completed to evaluate cognition. Cardiovascular function included measuring
both peripheral and central blood pressure and cerebral blood ﬂow. At the acute
time point, consumption of cocoa signiﬁcantly improved self-reported mental fatigue
and performance on the Serial Sevens task in cycle one of the CDB. No other
signiﬁcant effects were found. This trial was registered with the Australian and
New Zealand Clinical Trial Registry (Trial ID: ACTRN12613000626763). Accessible
via http://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12613000626763&
ddlSearch=Registered.
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Introduction
In recent years, there has been increasing attention given to the potential cognitive enhancing
beneﬁts of natural interventions, speciﬁcally foods containing ﬂavonoids, the largest subclass
of polyphenol antioxidants. Flavonoids and ﬂavanols are abundant in the human diet, with
popular dietary sources including tea, fruits, berries and cocoa (Bravo, 1998). The consumption
of ﬂavanol rich foods has been shown to result in neurobiological eﬀects, improving aspects of
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learning, memory, and overall cognitive performance (Letenneur
et al., 2007; Macready et al., 2009; Nurk et al., 2009; Williams
and Spencer, 2012). In particular, cocoa and cocoa-containing
products comprise many diﬀerent forms of beneﬁcial ﬂavonoids
(Gu et al., 2004) and as such, there has been increasing research
aimed at uncovering the cognitive enhancing potential of high-
ﬂavanol cocoa.
It is important to diﬀerentiate between the terms cacao, cocoa
and chocolate. The raw seeds obtained from the Theobroma
cacao tree are referred to as cacao, however once these seeds
are processed by way of grinding or roasting the name changes
to cocoa (Latif, 2013). Chocolate confectionary involves further
processing and the addition of multiple other ingredients
including sugar and fat, resulting in a solid edible product
(Cooper et al., 2008). The seeds of the T. cacao tree are rich
in a subclass of polyphenol antioxidants known as ﬂavonoids,
speciﬁcally catechin and epicatechin, as well as polymeric
units which comprise both catechin and epicatechin subunits,
which are collectively referred to as proanthocyanidins (or
procyanidins) (Steinberg et al., 2003; Nehlig, 2013). Cacao
seeds have been used medicinally for centuries. Writings of
the Mesoamerican civilizations describe the use of a beverage
made from cacao seeds for the treatment of many ailments
(Katz et al., 2011; Lippi, 2013). Cacao seeds were brought to
Europe by Spanish explorers (Lippi, 2009), where cocoa was
recognized for its health beneﬁts until the 20th century when
modern day manufacturing enabled the production of chocolate
confectionary to begin. Since then, chocolate has been perceived
as lacking nutritional value due to additional components such
as fats and sugar, however, if certain controlled processing
standards are implemented, substantial amounts of antioxidants
from the original cacao seed can be retained in some modern day
chocolates (Steinberg et al., 2003).
The human digestive system is able to readily absorb the
epicatechin component of ﬂavanol-rich cocoa, with blood plasma
concentrations peaking at 2–3 h following consumption (Nehlig,
2013). Epicatechin has been shown to cross the blood brain
barrier in animal studies (Abd El Mohsen et al., 2002), suggesting
that ﬂavonoids from the cacao bean have the ability to act
directly on the brain, which could potentially lead to cognitive
enhancement (Nehlig, 2013). Additional evidence from animal
studies on ﬂavanols in fruits such as grapes and berries found that
ﬂavanol consumption boosts memory and learning (Shukitt-Hale
et al., 2006, 2008; Joseph et al., 2007) by acting directly on
numerous receptors, kinases and transcription factors (Spencer,
2007, 2009). As such, ﬂavanols in cocoa may also have the
potential to act directly on the human brain and improve
aspects of cognitive performance through direct enhancement
of memory systems, just as the ﬂavanols in fruit have been
shown to do.
Cocoa may not only exert direct eﬀects on the brain, but
could potentially act indirectly through eﬀects to other bodily
systems. It has long been known that cocoa has beneﬁcial eﬀects
on the cardiovascular system, with initial evidence coming from
observational studies on the Kuna Indians, residing oﬀ the coast
of Panama. The Kuna are one of few remaining tribes who are
protected from vascular ailments, such as arterial hypertension
(Corti et al., 2009). It has been suggested that this is due to
the prominent role cocoa plays in the Kuna diet (Galleano
et al., 2009; Hollenberg et al., 2009), where they consume
the equivalent of ﬁve cups of liquid cocoa, or approximately
900mg cocoa ﬂavanols, per day (Pucciarelli, 2013). Research
demonstrated that when members of the Kuna relocated to
Panama, changing their culture and diet (in particular a reduced
dietary intake of ﬂavanol-rich cocoa), signiﬁcant increases in
blood pressure were subsequently observed (Galleano et al., 2009;
Fraga et al., 2011). Clinical investigations have revealed that
supplementation with ﬂavanol-rich cocoa reliably improves a
variety of cardiovascular variables, including peripheral blood
pressure in pre-hypertensive and hypertensive patients (Taubert
et al., 2007; Hooper et al., 2008; Ried et al., 2010), as well as
in normotensive populations (Ried et al., 2012). Changes to
cerebral blood ﬂow (CBF) (Fisher et al., 2006; Sorond et al.,
2008) and ﬂow-mediated dilation (Faridi et al., 2008; Grassi
et al., 2008; Monahan et al., 2011; Njike et al., 2011) have
been observed following cocoa supplementation. Given the
strong links between vascular health and cognitive function
(Dinges, 2006), it is possible that cocoa may improve cognitive
performance indirectly through improvements to CBF and
vascular health.
Randomized controlled trials have investigated the possibility
that cognitive function may be improved following cocoa
consumption. A short term neuroimaging investigation in young,
healthy, female participants revealed that acute administration of
a high ﬂavanol cocoa beverage (172mg/day for 5 days) enhanced
the Blood Oxygen Level Dependent (BOLD) signal following
completion of a cognitive switching task (Francis et al., 2006).
Also using an acute intervention, Field et al. (2011) found that 2 h
after cocoa-ﬂavanol supplementation, young participants showed
enhanced performance on the accuracy component of a spatial
working memory task, as well as performance improvements
on a choice reaction time task. Cognitive performance has been
enhanced following cocoa beverage supplementation in elderly
people with mild cognitive impairment (Desideri et al., 2012).
In contrast, some studies have found no such cognitive eﬀects,
for instance, Pase et al. (2013) found no changes to cognitive
performance acutely or sub-chronically for either a 250 or 500mg
cocoa ﬂavanol dose in healthy participants (40–65 years). Crews
et al. (2008) found no cognitive eﬀects in a healthy, older
sample (>60 years) following a 6 week intervention with a cocoa
beverage (397.30mg ﬂavanols) and bar (357.41mg ﬂavanols).
More recently, however, Scholey et al. (2010) found acute
improvements in cognitive performance following a 520mg
cocoa ﬂavanol dose, in response to a high level of cognitive
demand. In this same study, cocoa ﬂavanols also reduced
self-reported mental fatigue. Both Pase et al. (2013) and Crews
et al. (2008) did not implement a mentally demanding task,
suggesting that cocoa may only improve cognitive performance
in healthy populations when participants are subjected to
sustained eﬀortful processing.
The aim of the current randomized, controlled, double-blind
clinical trial was to assess both the acute (2 h post dose), and
sub-chronic (30 day post dose) eﬀects of cocoa supplementation
on mood and mental fatigue, cognitive performance and
cardiovascular function in a young, healthy sample. Unlike
previous clinical trials investigating cocoa and cognition, the
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current trial provided participants with either a visually identical
cocoa or true placebo tablet without ﬂavanols. By providing the
supplement in tablet form, participant expectation is removed as
they cannot visually decipher which treatment is the placebo and
which is active, compared to other trials which used dark and
white chocolate supplements (Field et al., 2011). Additionally,
by making use of a tablet, other potentially active ingredients
like sugars and fats can be excluded in order to make sure
that any resulting eﬀects can reliably be attributed to cocoa
ﬂavanols, and not to any of the other components found in
commercial chocolate or other styles of intervention such as
chocolate drinks (Francis et al., 2006; Crews et al., 2008; Scholey
et al., 2010; Desideri et al., 2012; Pase et al., 2013). Participants
were randomly allocated to receive tablets containing either
250 or 0mg (placebo) cocoa-ﬂavanols. It was hypothesized
that, compared to placebo, cocoa would improve cognitive
performance and mood.
Methods
Participants
Young, healthy participants aged 18–40 years (M = 24.13,
SD = 4.47), residing in Melbourne, Australia, were recruited
through magazine and social media advertisements, phone
calls, and emails. Potential participants expressing interest in
the study were screened for the following inclusion criteria:
not currently suﬀering medically diagnosed cardiovascular or
cognitive impairment, bleeding disorders, or gastrointestinal
disorders; no clinically signiﬁcant pulmonary, cardiovascular,
psychiatric, or neurological conditions in the past 12 months;
not taking any illicit drugs, cognitive enhancing medication,
or herbal supplements; not pregnant or lactating; not color
blind; not taking antidepressants, antipsychotics, anxiolytics,
or anticoagulants; hold a good working knowledge of English
language. Of the 40 recruited participants, 38 returned for
sub-chronic assessment (see Figure 1).
Design
The current trial investigated the eﬀects of cocoa
supplementation on cognitive and cardiovascular functioning
using a randomized, placebo-controlled, double-blind, parallel
design over a four-week period. Participants were randomly
allocated to receive one of two daily treatments:
(1) Active cocoa tablet (3058mg T. cacao seed extract
standardized to contain 250mg catechin polyphenols
and 5.56mg caﬀeine).
(2) Placebo tablet (Identical in appearance, size, texture and
color to cocoa tablet, containing inert cellulose powder).
The active and matching placebo supplements used in this
clinical trial were provided by Swisse Wellness Pty. Ltd.
(Melbourne, Australia). Participants were required to take one
active (or matching placebo) tablet daily for 4 weeks. The tablets
were presented in visually identical bottles, diﬀering only in
the labels, which depicted the participant ID number as well
as a code relating to the relevant group allocation. The placebo
tablets were identical to the active tablets, and blinding success
of participants was evaluated at the conclusion of the study using
a questionnaire. Participants were randomly assigned to receive
either active or placebo tablets using a computer generated
permuted block randomization schedule. Randomization was
performed by an independent statistical consultant that had
no involvement in the trial, and supplement bottles were
labeled according to the randomization schedule. The blinding
code was only revealed after analysis of the main study
outcomes.
Outcome Measures
The present study investigated the eﬀect of cocoa
supplementation on mood, cognitive and cardiovascular
function between baseline and acute (same day, 2 h after
ingestion of trial tablets), and baseline and sub-chronic (daily for
4 weeks) testing sessions. The primary outcomes were cognitive
performance, measured using the Swinburne University
Computerized Cognitive Assessment Battery (SUCCAB)
(Pipingas et al., 2010), mood, mental fatigue and stress, using the
Cognitive Demand Battery (CDB). Secondary outcomes were
cardiovascular markers, including blood pressure and cerebral
blood ﬂow.
Cognitive Assessment
Swinburne University Computerized Cognitive
Assessment Battery (SUCCAB)
Participants completed eight computer-based tasks from the
SUCCAB to assess various aspects of cognitive performance
(Pipingas et al., 2010). A 4-button response box was used
to complete the tasks, with each button representing a color
(red, blue, green or yellow), “yes” or “no,” or the spatial
location of objects on the screen (top, bottom, left or
right).
Instructions were presented at the beginning of each of the
tasks, which were read aloud to participants by the experimenter.
All tasks except the delayed recall task were preceded by a practice
trial where participants could experience an example of the task
and ask any questions. Each of the eight tasks was scored by
calculating the average reaction time and per cent accuracy, and
are described below in further detail.
(1) Simple reaction time: A single white square appeared in
the center of the computer screen 30 times at randomized
intervals. The “yes” button was required to be pressed as soon
as the square stimulus was visible to participants.
(2) Choice reaction time: Either a blue triangle or red square
appeared in the center of the computer screen with the order
and timing of the stimuli being randomized. Responses were
recorded by the pressing of either the blue or red buttons
corresponding with the stimuli’s color. This task assessed
participants’ visual perception decision time.
(3) Immediate recognition: Forty successive images were
presented in the center of the computer screen. After the
viewing period, participants were required to respond a
second series of successive images with either “yes” or “no”
buttons, signaling whether or not they had just seen a given
image during the earlier viewing period. Half of these images
in the second series were from the original 40, and half
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FIGURE 1 | Study ﬂow diagram.
were novel stimuli. This task was a non-verbal assessment
of recognition memory.
(4) Congruent Stroop color word: Randomized alternating trials
of stimulus words (red, yellow, blue, or green) in congruent
colors appeared on the computer screen (I.E. the word blue
would be presented in blue ink). To respond, the color button
that corresponded to the color of the word, not the physical
presentation of the word itself needed to be pressed. This task
assessed participants’ executive functioning and inhibition,
as they had to ignore the reﬂex of reading the word and focus
instead on the color it was presented in.
(5) Incongruent Stroop color word: Conducted in the same way
as congruent Stroop color word, except that the stimulus
words (red, yellow, blue, or green) appeared in incongruent
colors on the computer screen. (I.E. the word blue could
be presented in red, green or yellow ink, but not blue ink).
Participants’ skills in executive functioning and inhibition
are more vigorously tested in these incongruent trials.
(6) Spatial working memory: A 4 × 4 white grid was displayed
against a black background, with six of the grid positions
ﬁlled with solid white squares. The aim was to remember
where these squares were located during a brief viewing
period. The grid then became blank, and a series of four
white squares were presented one at a time in varying grid
locations. Participants responded with either the “yes” or
“no” buttons indicating if the new squares were presented
in the same locations as the original set. This task assessed
participants’ ability to hold spatial information in working
memory.
(7) Contextual memory: A series of 20 everyday pictures that
were positioned at either the top, bottom, left, or right of
the computer screen were shown against a black background.
After the viewing period, the same images were randomly
presented in the center of the computer screen. Participants
responded using either the top, bottom, left, or right buttons
to indicate the image’s original location on the screen. This
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task assessed participants’ episodic memory capabilities, as
they needed to recall the spatial location of the original
stimuli.
(8) Delayed recognition: The immediate recognition task
described earlier was repeated at the end of the testing
battery without a practice trial. Participants were shown the
remaining original 20 images and another 20 novel images,
and were again required to respond “yes” or “no” as to
whether or not they had viewed them earlier. As in the
immediate recognition task, this also assessed recognition
memory.
Cognitive Demand Battery (CDB)
The CDB is used to evaluate cognitive function by placing
participants under mental load. Moreover, this battery is
designed to assess mental fatigue (and mood) resulting from
the ongoing mental load. This battery involves the completion
of two serial subtraction tasks (serial threes and serial sevens),
the Bakan Rapid Visual Information Processing Task (RVIP)
and a mental fatigue visual analog scale (Kennedy and Scholey,
2004). Research has shown that while completing this battery,
participants’ task performance gradually declines whilst they
report feeling more mentally fatigued. Many studies looking at
the cognitive eﬀects of various dietary interventions have shown
that this decline can be somewhat mitigated by supplementation.
Figure 2 displays the structure of the CDB. There are three
main components to the CDB (Serial Threes, Sevens and RVIP),
which are both preceded and followed by a mental fatigue
assessment.
(1) Mental fatigue scales: Initially, participants are allocated
1min to rate their current state of mental fatigue and stress,
by marking a point on a computerized 100mm Visual
Analog Scale (VAS), with the left hand end of the scale
labeled “not at all,” and the right hand end of the scale labeled
“very much so.”
(2) Serial Threes subtraction task: Participants are presented
with a given number ranging between 800 and 999, and
are required to use the number keys on the keyboard to
count backwards by threes from this number as quickly
and as accurately as possible. The original starting number
is cleared from the screen upon entry of participants’ ﬁrst
response. Two minutes are allocated for this task and
participants are scored based on the number of correct
responses, errors and speed of response.
(3) Serial Sevens subtraction task: This task is identical in format
to the Serial Threes subtraction task, however it required
participants to count backwards by sevens. Two minutes
were also allocated for this task.
(4) Rapid Visual Information Processing Task (RVIP):
Participants are required to observe a continuous
presentation of single digits for targets of any three
consecutive odd or even digits. One hundred digits were
presented each minute and participants responded to the
detection of targets by pressing the spacebar as quickly as
possible. This task runs for 5min and is scored based on the
number of correctly detected targets, number of errors and
number of false alarms.
(5) Mental fatigue scales: Participants were again required to rate
their current subjective mental fatigue and stress on the same
100mm VAS used at the beginning of the CDB.
The duration for one cycle of the CDB is 10min. Participants
in the present study completed three cycles, resulting in a total
duration of 30min.
Cardiovascular Measures
Blood Pressure
Blood pressure was assessed in a quiet, dedicated university
laboratory following a ﬁve-minute rest period completed by
participants in the supine position on an examination bed.
The non-invasive SphygmoCor XCEL (AtCor Medical, Sydney,
Australia) device and software was used to attain participants’
peripheral and central aortic blood pressures, by applying the
cuﬀ to participants’ right arm, over the brachial artery. The
SphygmoCor XCEL takes three measurements of brachial blood
pressure for each participant, each separated by a thirty second
delay. The ﬁrst measurement is discarded, while the second and
third are averaged to provide a more accurate ﬁnal reading.
The SphygmoCor XCEL provides a valid estimation of central
aortic blood pressure using the brachial cuﬀ volume displacement
waveform method (Butlin et al., 2012).
FIGURE 2 | Presentation order of the three CDB cycles. RVIP, Rapid Visual Information Processing.
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Cerebral Blood Flow
Also using a dedicated university laboratory, a non-invasive
transcranial Doppler (Compumedics DWL, CA, USA) with a
4-MHz probe was used to record cerebral blood ﬂow velocity
in the common carotid artery (CCA). Experimenters recorded
the ﬂow through the CCA for approximately 2min in order
to calculate the resting mean CCA blood ﬂow velocity in
centimeters per second.
Procedure
Participants completed a total of three testing sessions; baseline
and acute assessment which took place on the same day
(2–3.5 h after tablet ingestion), and sub-chronic assessment
which was completed four-weeks after the initial testing date.
Participants consumed their allocated treatment daily for 30
days. Participants were instructed to abstain from caﬀeinated
products from the night prior to each testing session, as well as
abstaining from consuming any food or drink with the exception
of water for the duration of each of the testing days. The
current trial implemented procedures, which were conducted
in accordance with the Declaration of Helsinki (as revised
in 2004). The Swinburne University Human Research Ethics
Committee approved the trial, and written informed consent
was obtained from all participants prior to the commencement
of testing.
The ﬁrst testing day included both baseline and acute
assessment and ran for approximately 5 h, while the follow-
up testing day involved sub-chronic assessment, which required
approximately one and a half hours. All three testing sessions are
outlined in Figure 3.
FIGURE 3 | Testing day structure. BMI, Body Mass Index; SUCCAB, Swinburne University Computerized Cognitive Assessment Battery; CDB, Cognitive Demand
Battery.
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At the completion of the acute session, an appointment time
for the post four-week testing session was scheduled, planned for
the same time of day as the ﬁrst testing session. Additionally,
participants were instructed to take their ﬁnal supplement tablet
the day prior to the scheduled ﬁnal testing session.
The follow up sub-chronic testing session was conducted
exactly 4 weeks after the initial session. The session was
conducted in a way synonymous to the baseline session.
Participants were reminded to not consume any supplement
tablets on the day of sub-chronic testing. This way, experimenters
could be certain that they were measuring the sub-chronic, and
not acute eﬀects of cocoa. At the completion of the ﬁnal testing
session participants completed a questionnaire that evaluated
their tolerability to the supplement over the four-week period,
as well as the blinding success of group allocation. Participants
were then reimbursed for their time and travel expenses with a
$30 voucher.
Sample Size Calculations
A power-analysis was performed based on eﬀect sizes obtained
from Scholey et al. (2010)’s study. For mental fatigue, Scholey
et al. (2010) reported eﬀect sizes ranging from 0.33 to 0.42. To
be 95% conﬁdent in ﬁnding a signiﬁcant eﬀect (d = 0.33)
of cocoa supplementation on mental fatigue, a sample size
of 26 participants (13 per group) was deemed suﬃcient. For
cognitive performance Scholey et al. (2010) reported eﬀect sizes
ranging from 0.30 to 0.53. For this measure, a sample size of
32 participants (16 per group) was considered suﬃcient to be
95% conﬁdent in detecting a signiﬁcant eﬀect (d = 0.30). It was
decided that a sample of 40 participants (20 per group) would
allow for a 20% attrition rate, while also being powerful enough
to have 95% conﬁdence in detecting signiﬁcant eﬀects.
Statistical Analysis
SPSS version 21 (IBM, New York, NY, USA) was used to
compile and analyse all data. The data was ﬁrst screened for any
potential outliers, which were subsequently removed. Analyses
of co-variance (ANCOVAs) were used to examine potentially
signiﬁcant diﬀerences between groups at the both the two-
hour acute, and four-week sub-chronic time points, while taking
baseline measures into account as a covariate. Additionally,
post hoc independent samples t-tests were used to compare the
characteristics of the treatment groups at baseline, while post
hoc paired samples t-tests were used to compare any signiﬁcant
diﬀerences found when comparing baseline to acute or to sub-
chronic assessment time points. All results were considered
signiﬁcant at p < 0.05. All p-values are calculated two-tailed.
Results
Sample Characteristics
Table 1 displays the means and standard deviations for the
two groups across baseline demographic variables. ANCOVAs
revealed no signiﬁcant between-group diﬀerences at baseline.
Also noteworthy is that the sample had normal blood pressure
levels at baseline.
Acute Analysis
SUCCAB
No signiﬁcant between-group diﬀerences were found for
accuracy or reaction time in any SUCCAB task at the acute time
point when co-varying for baseline data (Table 2).
CDB
Prior to commencing the CDB, participants receiving cocoa
supplementation reported feeling signiﬁcantly less mentally
fatigued at the beginning of the battery, compared to participants
receiving placebo supplementation (Table 3).
Figure 4 displays participants responses to the question “How
mentally fatigued do you feel right now,” which were found to
be signiﬁcantly diﬀerent at the acute-pre CDB time point in the
ANCOVA analysis presented in Table 3. Post hoc independent
samples t-tests revealed that while the treatment groups were
not signiﬁcantly diﬀerent at baseline [t(37) = 0.62, p = 0.54],
participants receiving cocoa reported being signiﬁcantly less
mentally fatigued (M = 49.00, SD = 22.33) than participants
receiving placebo supplementation (M = 63.17, SD = 11.59)
at the acute pre-CDB time point [t(29.16) = −2.49, p = 0.02].
While the groups were not signiﬁcantly diﬀerent in the ANCOVA
analysis at the acute post-CDB time point, Figure 4 shows
that both groups did report being more mentally fatigued after
completing the acute CDB compared to previous time points,
with participants in the placebo group reporting feeling more
mentally fatigued than participants receiving cocoa.
Signiﬁcant between-group diﬀerences were found for the
Serial Sevens task at the acute time point when co-varying for
baseline, with participants receiving cocoa providing signiﬁcantly
more correct answers than those in receiving placebo. No
signiﬁcant between-group diﬀerences were observed during
cycles two and three of the CDB (Table 4).
Cardiovascular Measures
No signiﬁcant eﬀects were found for any of the cardiovascular
measures at the acute time point when co-varying for baseline
data (Table 5).
Sub-chronic Analysis
SUCCAB
No signiﬁcant between-group diﬀerences were found for
accuracy or reaction time in any SUCCAB task at the sub-chronic
time point when co-varying for baseline data (Table 6).
CDB
Looking at sub-chronic data after the third cycle of the CDB,
participants receiving the placebo reported feeling signiﬁcantly
less stressed compared to those receiving cocoa (Table 7).
Post-hoc independent samples t-tests revealed that the treatment
groups were not signiﬁcantly diﬀerent at baseline [t(34) = −1.83,
p = 0.08] or sub-chronic [t(34) = 0.54, p = 0.59] assessment.
Further post hoc paired t-test analyses were subsequently
completed to compare stress levels over time separately for
each of the groups. Results revealed that while the participants
receiving cocoa did not report any signiﬁcant changes in
subjective stress levels over time [t(17) = −0.88, p =
0.39], participants receiving placebo supplementation did report
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TABLE 1 | Baseline means and standard deviations across each treatment condition.
Cocoa Placebo Overall
M SD M SD M SD
DEMOGRAPHIC VARIABLES
Gender (%)
Males 20 12.5 32.5
Highest completed education (%)
Secondary school 5 10 7.5
Technical school 10 10 10
Bachelor degree 80 75 77.5
Postgraduate degree 5 5 5
Age (years) 24.35 4.75 23.90 4.28 24.13 4.47
BMI 22.40 3.07 23.60 3.19 23 3.15
CARDIOVASCULAR VARIABLES
CCA velocity, cm/s 21.60 6.33 21.43 7.14 21.52 6.65
Heart rate, bpm 68.10 11.46 76.00 15.36 72.05 13.96
Systolic BP, mmHg 116.50 10.55 121.70 11.77 119.10 11.34
Diastolic BP, mmHg 70.00 9.66 71.45 8.86 70.73 9.18
Central systolic BP, mmHg 102.00 10.38 106.10 9.84 104.05 10.20
Central diastolic BP, mmHg 70.15 10.13 73.80 10.92 71.98 10.56
Mean arterial pressure, mmHg 83.65 10.64 88.05 11.40 85.85 11.11
Pulse pressure, mmHg 32.30 7.61 32.30 6.07 32.30 6.79
Augmented pressure, mmHg 2.47 3.84 2.44 2.53 2.46 3.22
Augmentation index, % 6.95 13.23 8.00 7.84 7.46 10.81
CCA, Common Carotid Artery; BP, Blood Pressure; mmHg, Millimeters of Mercury.
TABLE 2 | Acute effects of cocoa supplementation on cognition: SUCCAB task accuracy and reaction time.
Cocoa Placebo
Baseline (0 h) Acute (2 h) Baseline (0 h) Acute (2 h) ANCOVA
M SD M SD M SD M SD F p
TASK ACCURACY (%)
Simple reaction time 99.75 1.12 95.83 6.24 96.95 5.69 96.87 5.25 1.66 0.21
Complex reaction time 85.21 11.75 75.26 14.86 77.45 12.63 77.05 13.39 0.95 0.34
Immediate recognition 79.65 10.94 84.56 7.79 73.50 11.92 80.67 9.89 0.33 0.57
Congruent stroop 97.82 2.67 96.32 7.22 99.23 1.46 98.08 1.84 0.96 0.96
Incongruent stroop 97.63 2.43 93.68 4.03 98.00 4.18 94.63 4.00 0.41 0.53
Spatial working memory 91.16 4.54 89.02 8.05 91.51 9.46 89.42 11.37 0.001 0.97
Contextual memory 81.75 14.07 82.50 12.72 87.89 10.18 86.11 11.06 0.12 0.73
Delayed recognition 76.44 9.34 70.50 12.32 68.28 10.30 73.25 9.40 4.34 0.05
TASK REACTION TIME (ms)
Simple reaction time 240.63 25.93 243.27 32.15 242.32 35.42 261.12 47.16 2.26 0.14
Complex reaction time 371.75 43.56 385.75 48.97 385.64 58.21 383.17 43.48 0.06 0.06
Immediate recognition 804.51 67.94 787.21 59.87 938.81 94.51 855.75 101.34 0.42 0.52
Congruent stroop 567.68 82.53 577.40 79.36 622.79 83.60 600.89 94.51 1.11 1.11
Incongruent stroop 660.83 87.55 675.17 104.37 683.74 89.51 669.65 94.89 0.76 0.39
Spatial working memory 693.90 79.66 651.73 84.71 737.65 107.38 679.96 88.21 0.002 0.97
Contextual memory 816.08 97.93 782.29 84.25 817.95 122.32 837.41 109.11 3.56 0.07
Delayed recognition 982.17 100.70 847.36 83.13 1029.26 154.85 894.49 97.61 0.73 0.40
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TABLE 3 | Acute effects of cocoa supplementation on self-reported
mental fatigue and stress, before and after the cognitive demand battery.
Group Baseline (0 h) Acute (2 h) ANCOVA
M SD M SD F p
BEFORE CDB
Mental fatigue Cocoa 49.40 16.22 49.00 22.33 12.21 0.004*
Placebo 46.26 15.38 63.17 11.59
Stress Cocoa 22.70 14.43 31.30 14.62 0.50 0.50
Placebo 29.94 14.89 38.94 17.17
AFTER CDB
Mental fatigue Cocoa 64.00 17.82 62.05 17.48 0.23 0.63
Placebo 70.32 16.04 66.89 15.70
Stress Cocoa 37.00 18.63 31.30 18.71 0.54 0.47
Placebo 47.94 16.68 41.65 16.56
CDB, Cognitive Demand Battery. *p < 0.05.
FIGURE 4 | Participants average response to the question “how
mentally fatigued do you feel right now” both before, and after acute
tablet consumption. (For mental fatigue, responses to the question range
from 1 = “not at all” to 100 = “very much so”). Signiﬁcant differences
compared to placebo are indicated (*p < 0.05). CDB, Cognitive Demand
Battery.
signiﬁcantly lower levels of stress after completing the CDB at
sub-chronic assessment relative to baseline [t(16) = 3.43, p =
0.003].
During the ﬁrst, second and third cycles of the CBD, there
were no signiﬁcant between-group diﬀerences for any of the tasks
at the sub-chronic time point when co-varying for baseline data
(Table 8).
Cardiovascular Measures
No signiﬁcant eﬀects were found for any of the cardiovascular
measures at the sub-chronic time point when co-varying for
baseline data (Table 9).
Discussion
This randomized, placebo-controlled, double-blind clinical trial
investigated both the acute and sub-chronic eﬀects of cocoa
supplementation on cognitive performance. Consumption of
250mg cocoa ﬂavanols improved performance acutely on the
Serial component of the Cognitive Demand Battery (CDB)
in cycle one only. Furthermore, acute cocoa supplementation TA
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TABLE 5 | Acute effects of cocoa supplementation on cardiovascular measures.
Cocoa Placebo ANCOVA
Baseline (0 h) Acute (2 h) Baseline (0 h) Acute (2 h)
M SD M SD M SD M SD F p
CARDIOVASCULAR MEASURES
CCA velocity, cm/s 21.60 6.33 20.39 6.76 21.43 7.14 23.64 5.71 3.19 0.09
Heart rate, bpm 68.10 11.46 64.05 12.36 76.00 15.36 70.05 14.06 0.02 0.89
Systolic BP, mmHg 116.50 10.55 119.10 9.04 121.70 11.77 120.65 8.24 0.47 0.50
Diastolic BP, mmHg 70.00 9.66 68.80 6.62 71.45 8.86 69.60 7.26 0.003 0.96
Central systolic BP, mmHg 102.00 10.38 103.35 8.73 106.10 9.84 104.45 6.68 0.42 0.42
Central diastolic BP, mmHg 70.15 10.13 69.85 7.06 73.80 10.92 70.70 7.96 0.53 0.47
Mean arterial pressure, mmHg 83.65 10.64 82.75 7.93 88.05 11.40 84.40 8.26 0.47 0.50
Pulse pressure, mmHg 32.30 7.61 33.50 4.54 32.30 6.07 33.85 6.56 0.06 0.81
Augmented pressure, mmHg 2.47 3.84 2.37 3.40 2.44 2.53 2.31 2.89 0.002 0.97
Augmentation index, % 6.95 13.23 6.74 10.06 8.00 7.84 7.38 9.29 0.001 0.98
CCA, Common Carotid Artery; BP, Blood Pressure; mmHg, Millimeters of Mercury.
TABLE 6 | Sub-chronic effects of cocoa supplementation on cognition: SUCCAB task accuracy and reaction time.
Cocoa Placebo ANCOVA
Baseline (0 h) Sub-chronic (4 week) Baseline (0 h) Sub-chronic (4 week)
M SD M SD M SD M SD F p
TASK ACCURACY (%)
Simple reaction time 99.74 1.15 97.50 3.93 96.79 5.80 96.76 5.85 1.03 0.32
Complex reaction time 84.43 11.53 80.53 11.77 76.32 11.88 75.28 12.30 0.68 0.42
Immediate recognition 78.89 10.72 79.84 13.70 72.98 12.01 78.49 11.84 0.34 0.56
Congruent stroop 97.84 2.74 96.84 3.21 99.19 1.49 98.55 1.92 0.61 0.22
Incongruent stroop 97.50 2.43 94.31 3.91 98.82 2.10 95.00 2.89 0.002 0.96
Spatial working memory 90.88 4.49 93.47 5.50 91.07 9.50 90.30 9.65 2.34 0.14
Contextual memory 80.79 13.78 87.50 12.98 87.50 10.33 88.61 8.19 0.02 0.90
Delayed recognition 75.90 9.27 74.17 19.34 68.28 10.30 72.01 18.04 0.81 0.38
TASK REACTION TIME (ms)
Simple reaction time 240.46 26.63 240.13 40.91 242.16 36.50 254.62 46.68 0.79 0.38
Complex reaction time 374.66 42.71 363.89 31.16 385.64 58.21 367.62 40.93 0.10 0.76
Immediate recognition 809.05 66.87 807.15 85.12 939.34 97.07 843.12 79.44 0.56 0.46
Congruent stroop 570.80 83.57 594.43 92.39 625.60 84.91 614.38 85.43 1.59 0.44
Incongruent stroop 667.32 85.26 662.20 108.35 680.43 90.70 680.14 69.05 0.30 0.59
Spatial working memory 695.85 81.35 641.06 82.61 743.67 106.79 694.15 89.73 0.62 0.44
Contextual memory 820.07 98.93 778.84 99.84 822.32 124.33 793.79 95.15 0.25 0.62
Delayed recognition 983.40 103.31 849.41 108.80 1029.26 154.85 901.04 124.46 0.74 0.40
signiﬁcantly reduced participants’ self-reported mental fatigue
prior to commencing the CDB testing battery. Following
completion of the CDB at sub-chronic assessment, participants
receiving the placebo supplement reported feeling signiﬁcantly
less stressed compared to participants supplemented with cocoa.
No signiﬁcant eﬀects were found for cognitionmeasured with the
SUCCAB or cardiovascular function.
The acute improvements found in cognitive performance and
mental fatigue are in line with the acute ﬁndings of Scholey
et al. (2010). However, the present improvements in cognitive
performance were found during the Serial Sevens component
rather than for Serial Threes. Using a 520mg cocoa beverage
intervention, Scholey et al. (2010) found that participants
produced more correct responses during the Serial Threes task
throughout each of the six cycles (lasting 1 h, in comparison to
the present study’s three cycles lasting half an hour), with the
most signiﬁcant improvement seen during the fourth cycle at
just over 2 h post cocoa consumption. Signiﬁcant eﬀects were
also found for a 940mg beverage; however the eﬀect was weaker,
producing signiﬁcant improvements for the ﬁrst four cycles only.
We found CDB eﬀects only in the ﬁrst cycle, whereas
Scholey et al. (2010) found eﬀects throughout six cycles. In
Frontiers in Pharmacology | www.frontiersin.org 10 May 2015 | Volume 6 | Article 93
Massee et al. Cocoa supplementation and cognitive function
TABLE 7 | Sub-chronic effects of cocoa supplementation on self-reported
mental fatigue and stress, before and after the cognitive demand battery.
Group Baseline (0 h) Sub-chronic ANCOVA
(4 week)
M SD M SD F p
BEFORE CDB
Mental fatigue Cocoa 51.05 14.83 54.53 16.07 0.70 0.41
Placebo 47.89 14.05 49.76 14.42
Stress Cocoa 22.63 14.82 39.21 21.44 1.00 0.33
Placebo 29.94 14.89 35.81 17.02
AFTER CDB
Mental fatigue Cocoa 64.79 17.94 66.33 23.35 0.60 0.44
Placebo 72.11 14.41 64.00 14.93
Stress Cocoa 36.95 19.14 40.56 22.64 5.50 0.03*
Placebo 47.94 16.68 36.06 16.08
CDB, Cognitive Demand Battery. *p < 0.05.
the current study, participants did not begin the CDB until
3 h after taking the cocoa supplement, whereas participants in
Scholey et al.’s (2010) study began the CDB one and a half
hours post-consumption. Participants in our study completed
the SUCCAB testing battery ﬁrst, as a way of mentally taxing
participants, before later completing the CDB. As the epicatechin
component of cocoa ﬂavanols peaks in concentration in human
blood plasma at 2–3 h post consumption (Francis et al., 2006;
Nehlig, 2013), it is possible that by completing the SUCCAB
ﬁrst, the CDB was pushed into a time frame where there were
diminished levels of epicatechin. Additionally, as Scholey et al.
(2010) used a much higher dose than was investigated in the
current study, it is possible that participants in the current study
had insuﬃcient levels of epicatechin during the testing period.
At the acute time point, participants supplemented with
cocoa reported feeling signiﬁcantly less mentally fatigued prior
to completing the CDB, than those receiving the placebo
supplement. As the CDB was the ﬁnal task in the testing
sequence and was undertaken four and a half hours after the
commencement of the experimental session, it is likely that
participants may have been feeling fatigued at this point. It
appears that at the time that mental fatigue was assessed, at 3 h
post consumption, cocoa ﬂavanols signiﬁcantly attenuated this
fatigue. While this eﬀect was not carried through to the fatigue
assessment after the CDB was completed, it is possible that this
too relates to the fact that epicatechin levels were likely to have
declined well past their peak eﬀect by the end of the CDB (Francis
et al., 2006; Nehlig, 2013),
Similar to results found by Crews et al. (2008),
supplementation with cocoa ﬂavanols did not produce any
cognitive sub-chronic eﬀects, with no signiﬁcant changes found
to performance on any of the CDB tasks or the SUCCAB test
battery. Additionally, no signiﬁcant changes to participants’
self-reported mental fatigue were observed. The lack of sub-
chronic eﬀects on cognitive performance is also consistent
with the ﬁndings of Pase et al.’s (2013). Interestingly, following
completion of the CDB, participants that received placebo TA
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TABLE 9 | Sub-chronic effects of cocoa supplementation on cardiovascular measures.
Cocoa Placebo ANCOVA
Baseline (0 h) Sub-chronic (4 week) Baseline (0 h) Sub-chronic (4 week)
M SD M SD M SD M SD F p
CARDIOVASCULAR MEASURES
CCA velocity, cm/s 21.23 6.32 19.00 6.14 21.18 7.28 21.24 6.46 1.06 0.31
Heart rate, bpm 68.00 11.76 69.00 12.74 77.11 14.94 74.44 18.67 0.27 0.60
Systolic BP, mmHg 117.47 9.87 122.84 9.65 121.42 12.02 120.50 7.95 2.05 0.16
Diastolic BP, mmHg 70.68 9.42 71.84 8.15 71.21 9.04 72.61 7.73 0.21 0.65
Central systolic BP, mmHg 103.11 9.37 107.21 8.62 105.84 10.04 106.11 7.38 0.85 0.36
Central diastolic BP, mmHg 70.84 9.91 72.84 8.35 73.63 11.19 71.56 13.17 0.34 0.56
Mean arterial pressure, mmHg 84.53 10.16 87.05 9.20 88.00 11.71 88.33 9.10 0.02 0.90
Pulse pressure, mmHg 32.74 7.56 34.37 5.73 32.21 6.22 35.50 16.54 0.11 0.75
Augmented pressure, mmHg 2.89 3.48 3.28 4.28 2.52 2.56 3.18 4.00 0.001 0.97
Augmentation index, mmHg 8.50 11.70 8.89 11.49 8.29 7.98 9.41 10.43 0.03 0.86
CCA, Common Carotid Artery; BP, Blood Pressure; mmHg, Millimeters of Mercury.
supplementation sub-chronically, reported feeling signiﬁcantly
less stressed than their cocoa counterparts. This result is
unexpected, and in the absence of other sub-chronic eﬀects, it
may simply be a chance ﬁnding. It is noteworthy that participants
had been instructed to abstain from the daily trial supplement on
the morning of the sub-chronic testing (1 month follow up). In
this way, any potential acute eﬀects were eliminated. Therefore,
our conclusions regarding the lack of sub-chronic eﬀects are
further bolstered by this aspect of the experimental design.
However, this does not eliminate the possibility that there may
be positive beneﬁts with a longer cumulative supplementation
period. Future studies should also consider the potential eﬀects
of acute, chronic and acute on chronic eﬀects.
The exact mechanism behind the action of cocoa ﬂavanols
is yet to be conclusively determined. One study suggested
that improvements in vascular health may partly underpin
improvements in cognition following cocoa supplementation in
adults who are in poor health (Desideri et al., 2012). However, in
young healthy adults, increases in cerebral blood ﬂow have been
reported in the absence of signiﬁcant behavioral eﬀects (Francis
et al., 2006). Although the present study did not ﬁnd any eﬀects
on blood ﬂow velocity through the common carotid artery using
Doppler, this measure may be relatively insensitive, as compared
to the more costly neuroimaging methods utilized by Francis
et al. It is also possible that the 250mg dose of cocoa ﬂavanols
used in this study was insuﬃcient to inﬂuence cardiovascular and
blood ﬂow changes.
The present study had a number of limitations. Despite
participants completing a practice run for each SUCCAB sub-
test during testing sessions, there was not a separate testing day
devoted to practice testing prior to the assessment of baseline
performance for all tasks. As such, the possibility of practice
eﬀects occurring in this sample cannot be eliminated. Larger
studies making use of a practice testing day are recommended to
conﬁrm the ﬁndings presented here. Additionally, the duration of
this trial was only 30 days. The possibility that longer intervention
periods may result in diﬀerent eﬀects cannot be ruled out. Future
studies may also beneﬁt from investigating the eﬀects of cocoa
supplementation using a higher dose, rather than the 250mg dose
used here. It is possible that the lack of cardiovascular eﬀects,
and subsequent lack of cognitive eﬀects seen here may be a result
of too low a dose of cocoa ﬂavanols. A study by Brickman et al.
(2014) for example, established a chronic, 3 month intervention
using a diet containing either high (900mg) or low (10mg) cocoa
ﬂavanols in healthy, older participants aged 50–69 years. It was
found that in the high ﬂavanol diet group, both dentate gyrus
function and cognitive performance on the ModBent task were
enhanced. It is possible that these ﬁndings were a result of the
higher dose used (900mg compared to 250mg in the present
study). It should also be noted that the cocoa supplement used
in the current study included 5.56mg of caﬀeine, whereas the
placebo did not. Although the eﬀects of such a small dose of
caﬀeine on cognition are unclear, future research could match the
placebo for caﬀeine content. Furthermore, the young age and size
of the present cohort may also have contributed to our lack of
cognitive and vascular ﬁndings.
In conclusion, a 250mg dose of cocoa ﬂavanols was found to
attenuate mental fatigue and improve minor aspects of cognitive
performance acutely but not sub-chronically during a highly
demanding task. Future research should assess a higher dose of
cocoa as well as cognitive, mood and cardiovascular eﬀects in an
older cohort.
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